- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05327114
Onderzoek naar werkzaamheid en veiligheid van nipocalimab bij volwassenen met chronische inflammatoire demyeliniserende polyneuropathie (CIDP)
Fase 2/3, multistage, multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde terugtrekkingsstudie met parallelle groepen om de werkzaamheid en veiligheid te evalueren van nipocalimab toegediend aan volwassenen met chronische inflammatoire demyeliniserende polyneuropathie (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Uitgebreide toegang
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
-
Buenos Aires, Argentinië, C1199ABB
- Actief, niet wervend
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentinië, C1428AQK
- Werving
- Instituto Fleni
-
Buenos Aires, Argentinië, C1428
- Voltooid
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentinië, 2900
- Werving
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australië, 3004
- Voltooid
- The Alfred Hospital
-
Parkwood, Australië, 4215
- Voltooid
- Gold Coast University Hospital
-
-
-
-
-
Ottawa, Canada, K1N 6N5
- Werving
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Beijing, China, 100191
- Voltooid
- Peking University Third Hospital
-
Beijing, China, 100034
- Voltooid
- Peking University First Hospital
-
Beijing, China, 100053
- Actief, niet wervend
- Xuanwu Hospital ,Capital Medical University
-
Beijing, China, 100070
- Actief, niet wervend
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, China, 130021
- Actief, niet wervend
- The First Hospital of Jilin University
-
Changsha, China, 410008
- Voltooid
- Xiangya Hospital Central South University
-
Changsha, China, 410008
- Actief, niet wervend
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, China, 610072
- Voltooid
- Sichuan Provincial Peoples Hospital
-
Chifeng, China, 024000
- Voltooid
- Chifeng Municipal Hospital
-
Fuzhou, China, 350001
- Actief, niet wervend
- Fujian Medical University Union Hospital
-
Guangzhou, China, 510080
- Actief, niet wervend
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, China, 250012
- Actief, niet wervend
- Qilu Hospital of Shandong University
-
Jinan, China, 250014
- Voltooid
- Qianfoshan hospital of Shandong Province
-
Nanchang, China, 330006
- Actief, niet wervend
- The First Affiliated Hospital of NanChang University
-
Shanghai, China, 200336
- Voltooid
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, China, 200040
- Actief, niet wervend
- Huashan Hospital Fudan University
-
Wuhan, China, 430023
- Voltooid
- Renmin Hospital of Wuhan University
-
Xi'an, China, 710032
- Voltooid
- Tangdu hospital the Fourth Military Medical
-
Xi'an, China, 710075
- Actief, niet wervend
- Xi 'an GaoXin Hospital
-
-
-
-
-
Floridablanca, Colombia, 681004
- Voltooid
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Colombia, 50021
- Actief, niet wervend
- Instituto Neurológico de Colombia
-
-
-
-
-
Berlin, Duitsland, 13347
- Actief, niet wervend
- Judisches Krankenhaus Berlin
-
Bochum, Duitsland, 44791
- Voltooid
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Duitsland, 6120
- Actief, niet wervend
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Duitsland, 30625
- Actief, niet wervend
- Medizinische Hochschule Hannover
-
Leipzig, Duitsland, 4103
- Voltooid
- Universitaetsklinikum Leipzig
-
Potsdam, Duitsland, 14471
- Voltooid
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Bordeaux, Frankrijk, 33000
- Voltooid
- CHU Bordeaux
-
Bron, Frankrijk, 69699
- Voltooid
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, Frankrijk, 94270
- Actief, niet wervend
- Hopital de Bicetre
-
Marseille, Frankrijk, 13385
- Actief, niet wervend
- Hopital de la Timone
-
Nice, Frankrijk, 06000
- Actief, niet wervend
- Hopital PASTEUR
-
Nîmes, Frankrijk, 30029
- Actief, niet wervend
- CHU Nimes Hopital Caremeau
-
Paris, Frankrijk, 75013
- Voltooid
- Hopital de la Pitie Salpetriere
-
Paris, Frankrijk, 75019
- Voltooid
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, Frankrijk, 67200
- Actief, niet wervend
- CHRU Strasbourg
-
-
-
-
-
Athens, Griekenland, 12462
- Werving
- Attikon General Hospital of Athens
-
Athens, Griekenland, 11527
- Voltooid
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Griekenland, 26504
- Voltooid
- Patras University Hospital
-
Thessaloniki, Griekenland, 54636
- Werving
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Catania, Italië, 95123
- Voltooid
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italië, 16132
- Voltooid
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italië, 20144
- Voltooid
- Casa di Cura del Policlinico
-
Milan, Italië, 20133
- Voltooid
- Istituto Neurologico Carlo Besta
-
Naples, Italië, 80131
- Actief, niet wervend
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italië, 10043
- Voltooid
- Aou San Luigi Gonzaga
-
Pavia, Italië, 27100
- Voltooid
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italië, 00168
- Voltooid
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italië, 20086
- Voltooid
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japan, 070-0901
- Actief, niet wervend
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japan, 113 8519
- Actief, niet wervend
- Institute of Science Tokyo Hospital
-
Chiba, Japan, 260-8677
- Voltooid
- Chiba University Hospital
-
Hamamatsu, Japan, 430-8558
- Actief, niet wervend
- Seirei Hamamatsu General Hospital
-
Isehara, Japan, 259-1193
- Actief, niet wervend
- Tokai University Hospital
-
Kobe, Japan, 650 0047
- Voltooid
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japan, 187-8551
- Actief, niet wervend
- National Center of Neurology and Psychiatry
-
Koshigaya, Japan, 343-8555
- Actief, niet wervend
- Saitama Medical Center
-
Kumamoto, Japan, 860-8556
- Voltooid
- Kumamoto University Hospital
-
Nagoya, Japan, 466-8560
- Actief, niet wervend
- Nagoya University Hospital
-
Nagoya, Japan, 455-8530
- Actief, niet wervend
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japan, 589 8511
- Voltooid
- Kindai University Hospital
-
Sendai, Japan, 983-8520
- Actief, niet wervend
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japan, 321 0293
- Voltooid
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japan, 162-8666
- Voltooid
- Tokyo Women's Medical University Hospital
-
Tenri, Japan, 632-0015
- Voltooid
- Tenri Hospital
-
Toon-shi, Japan, 791-0295
- Voltooid
- Ehime University Hospital
-
Toyama, Japan, 930-0194
- Voltooid
- Toyama University Hospital
-
Ube, Japan, 755-8505
- Voltooid
- Yamaguchi University Hospital
-
-
-
-
-
Monterrey, Mexico, 64710
- Voltooid
- i Can Oncology Center
-
Tlalnepantla, Mexico, 54055
- Werving
- Clinical Research Institute S.C.
-
-
-
-
-
Chorzów, Polen, 41 500
- Voltooid
- Centrum Medyczne
-
Krakow, Polen, 30 539
- Voltooid
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Polen, 20 093
- Voltooid
- Prywatny Gabinet Lekarski
-
Poznan, Polen, 61 731
- Actief, niet wervend
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Almada, Portugal, 2805-267
- Actief, niet wervend
- Hospital Garcia de Orta
-
Braga, Portugal, 4710-243
- Voltooid
- Hospital de Braga
-
Porto, Portugal, 4200 319
- Actief, niet wervend
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Alicante, Spanje, 03010
- Actief, niet wervend
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Spanje, 8035
- Voltooid
- Hosp Univ Vall D Hebron
-
Bilbao, Spanje, 48013
- Actief, niet wervend
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Spanje, 20014
- Voltooid
- Hosp. Univ. Donostia
-
Madrid, Spanje, 28040
- Voltooid
- Hosp. Clinico San Carlos
-
Seville, Spanje, 41009
- Actief, niet wervend
- Hosp. Virgen Macarena
-
-
-
-
-
Kaohsiung City, Taiwan, 88301
- Voltooid
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taiwan, 100
- Actief, niet wervend
- National Taiwan University Hospital
-
Taipei, Taiwan, 111
- Actief, niet wervend
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Hradec Králové, Tsjechië, 500 05
- Actief, niet wervend
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Tsjechië, 708 52
- Voltooid
- Fakultni Nemocnice Ostrava
-
Pardubice, Tsjechië, 53203
- Voltooid
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Birmingham, Verenigd Koninkrijk, B15 2TH
- Voltooid
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Verenigd Koninkrijk, EX2 5DW
- Voltooid
- Royal Devon & Exeter Hospital
-
Glasgow, Verenigd Koninkrijk, G514TF
- Actief, niet wervend
- NHS Greater Glasgow and Clyde
-
London, Verenigd Koninkrijk, NW3 2QG
- Voltooid
- Royal Free Hospital
-
Sheffield, Verenigd Koninkrijk, S10 2 JF
- Actief, niet wervend
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Colorado
-
Centennial, Colorado, Verenigde Staten, 80112
- Actief, niet wervend
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, Verenigde Staten, 33067
- Voltooid
- Healthcare Innovations Institute Inc
-
Maitland, Florida, Verenigde Staten, 32751
- Voltooid
- Neurology Associates PA
-
Miami, Florida, Verenigde Staten, 33136
- Actief, niet wervend
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Voltooid
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Voltooid
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Voltooid
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Voltooid
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Voltooid
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64128
- Voltooid
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Voltooid
- The Neurological Institute of New York
-
Patchogue, New York, Verenigde Staten, 11772
- Voltooid
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Voltooid
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- Actief, niet wervend
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78756
- Voltooid
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Actief, niet wervend
- Advocate Health - Aurora St. Luke's Medical Center
-
-
-
-
-
Seoul, Zuid -Korea, 05030
- Voltooid
- Konkuk University Medical Center
-
Seoul, Zuid -Korea, 02447
- Voltooid
- Kyunghee University Medical Center
-
Seoul, Zuid -Korea, 135-710
- Voltooid
- Samsung Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Andere namen:
|
|
Placebo-vergelijker: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Tijdsspanne: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Tijdsspanne: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Tijdsspanne: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Tijdsspanne: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Tijdsspanne: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Tijdsspanne: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tijdsspanne: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tijdsspanne: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Tijdsspanne: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Tijdsspanne: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Tijdsspanne: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Tijdsspanne: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Tijdsspanne: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tijdsspanne: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tijdsspanne: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Tijdsspanne: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Tijdsspanne: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Tijdsspanne: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het zenuwstelsel
- Pathologische processen
- Neuromusculaire aandoeningen
- Chronische ziekte
- Ziekte attributen
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Ziekten van het perifere zenuwstelsel
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Polyneuropathieën
- Polyradiculoneuropathie
- Pathologische aandoeningen, tekenen en symptomen
- Polyradiculoneuropathie, chronische inflammatoire demyeliniserende
Andere studie-ID-nummers
- CR109195
- 80202135CDP3001 (Andere identificatie: Janssen Research & Development, LLC)
- 2021-003234-37 (EudraCT-nummer)
- 2023-508425-28-00 (Register-ID: EUCT number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .